N I Nissen

606 total citations
15 papers, 496 citations indexed

About

N I Nissen is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, N I Nissen has authored 15 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in N I Nissen's work include Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). N I Nissen is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). N I Nissen collaborates with scholars based in Denmark, United States and Sweden. N I Nissen's co-authors include A. Gottlieb, Leon Stutzman, J Pedersen-Bjergaard, Jens Ersbøll, J. Struck, Cooper Mr, Lena Specht, Severin Olesen Larsen, Glicksman As and J F Holland and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

N I Nissen

15 papers receiving 448 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N I Nissen Denmark	8	298	148	143	142	114	15	496
Marcel Hayat France	12	264 0.9×	168 1.1×	135 0.9×	160 1.1×	80 0.7×	20	579
P. Gobbi Italy	12	329 1.1×	87 0.6×	99 0.7×	195 1.4×	40 0.4×	20	469
José C. Díaz‐Maqueo Mexico	12	261 0.9×	98 0.7×	52 0.4×	294 2.1×	89 0.8×	34	529
J H Glick United States	13	249 0.8×	101 0.7×	85 0.6×	288 2.0×	66 0.6×	23	623
JJ Spinelli Canada	8	158 0.5×	330 2.2×	144 1.0×	184 1.3×	61 0.5×	12	543
F. B. Hagemeister United States	10	304 1.0×	56 0.4×	109 0.8×	329 2.3×	45 0.4×	25	564
Marzia Salvucci Italy	15	321 1.1×	289 2.0×	53 0.4×	214 1.5×	146 1.3×	27	716
P. J. Bierman United States	11	340 1.1×	255 1.7×	76 0.5×	248 1.7×	61 0.5×	21	592
Murphy Sb United States	7	470 1.6×	145 1.0×	71 0.5×	237 1.7×	284 2.5×	10	695
P. Salvador United States	7	620 2.1×	69 0.5×	171 1.2×	386 2.7×	182 1.6×	7	840

Countries citing papers authored by N I Nissen

Since Specialization

Citations

This map shows the geographic impact of N I Nissen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N I Nissen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N I Nissen more than expected).

Fields of papers citing papers by N I Nissen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N I Nissen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N I Nissen. The network helps show where N I Nissen may publish in the future.

Co-authorship network of co-authors of N I Nissen

This figure shows the co-authorship network connecting the top 25 collaborators of N I Nissen. A scholar is included among the top collaborators of N I Nissen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N I Nissen. N I Nissen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Ehmsen, Sidse, Sofie Traynor, N I Nissen, et al.. (2025). RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer. Frontiers in Oncology. 14. 1497093–1497093. 1 indexed citations

Nissen, N I, et al.. (2025). Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells. Journal of Personalized Medicine. 15(7). 271–271. 2 indexed citations

Glicksman, Arvin S., Bruce E. Peterson, N I Nissen, et al.. (1996). 24 Augmented therapy of extensive Hodgkin's disease: Radiation to bulk disease or prolongation of induction chemotherapy did not improve survival. International Journal of Radiation Oncology*Biology*Physics. 36(1). 170–170. 1 indexed citations

Birgens, Henrik, B. Egelund Christensen, Nicklas Hansen, et al.. (1991). [Malignant hematologic diseases. Diagnosis and treatment. A clearing report].. PubMed. 153(23). 1638–47. 1 indexed citations

Pedersen-Bjergaard, J, Preben Philip, Vibeke Ravn, Steen Werner Hansen, & N I Nissen. (1988). Therapy-related acute nonlymphocytic leukemia of FAB type M4 or M5 with early onset and t(9;11) (p21;q23) or a normal karyotype: a separate entity?. Journal of Clinical Oncology. 6(2). 395–397. 18 indexed citations

Pedersen-Bjergaard, J, Severin Olesen Larsen, J. Struck, et al.. (1987). RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE. The Lancet. 330(8550). 83–88. 168 indexed citations

Vinciguerra, V., Kathleen J. Propert, Morton Coleman, et al.. (1986). Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B.. Journal of Clinical Oncology. 4(6). 838–846. 33 indexed citations

As, Glicksman, et al.. (1982). Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study.. PubMed. 66(4). 1035–44. 124 indexed citations

Bloomfield, C. D., T F Pajak, Arvin S. Glicksman, et al.. (1982). Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies.. PubMed. 66(4). 835–46. 43 indexed citations

10.

Peterson, B. A., Thomas F. Pajak, M. R. Cooper, et al.. (1982). Effect of age on therapeutic response and survival in advanced Hodgkin's disease.. PubMed. 66(4). 889–98. 67 indexed citations

11.

Hansen, Mads, C. D. Bloomfield, Judit Jørgensen, et al.. (1981). VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.. PubMed. 64(10-11). 1135–7. 11 indexed citations

12.

Vinciguerra, V., Morton Coleman, Thomas F. Pajak, et al.. (1981). MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study.. PubMed. 4(2). 99–105. 1 indexed citations

13.

Nissen, N I, et al.. (1972). Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent.. PubMed. 56(2). 229–35. 18 indexed citations

14.

Nissen, N I, et al.. (1965). ORAL TREATMENT OF A-V BLOCK AND OTHER BRADYCARDIAS WITH SUSTAINED ACTION ISOPRENALINE. Heart. 27(6). 926–931. 5 indexed citations

15.

Nissen, N I. (1960). Influence of CO2 on Respiratory Metabolism of Ehrlich Ascites Tumor.. Experimental Biology and Medicine. 104(3). 446–448. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact